Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patients

FRANK CHEAU-FENG LIN2026-10-162026-10-162022-03-01Pure ID: 15325487Pure UUID: c0227637-2241-4b14-b8d6-85f4ce70d0da10.1016/j.oraloncology.2022.105729https://www.scopus.com/pages/publications/85124331719https://scholars.csmu.edu.tw/handle/123456789/30939enPrognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio during immune checkpoint inhibitor treatment in recurrent or metastatic head and neck squamous cell carcinoma patientsjournal article